Capricor to Present Long-Term Deramiocel Data at WMS 2026 Ahead of BLA Decision
Event summary
- Capricor will present 24-month HOPE-3 and open-label extension data for Deramiocel at WMS 2026 (Sept 29 - Oct 3)
- 82 of 106 patients reached the 24-month time point, with 40 originally assigned to Deramiocel and 42 to placebo
- Data includes delayed-start and natural history analyses submitted in recent BLA amendment
- PDUFA target action date for Deramiocel BLA is November 22, 2026
- Capricor will also present two preclinical posters from its StealthX™ exosome platform
The big picture
Capricor's presentation of long-term Deramiocel data comes as the company awaits a regulatory decision for its lead asset in Duchenne muscular dystrophy. The timing is critical, as positive results could strengthen Capricor's position in the rare disease space ahead of potential competition from Nippon Shinyaku and NS Pharma. The company's exosome platform represents a longer-term growth opportunity beyond Deramiocel.
What we're watching
- Regulatory Timeline
- Whether the November 22, 2026 PDUFA date will hold given the recent BLA amendment
- Clinical Efficacy
- How the 24-month data compares to 12-month results and natural history benchmarks
- Pipeline Progress
- The pace at which Capricor advances its StealthX™ exosome platform
Related topics